

Overview

Method Name

Direct Radioimmunoassay

NY State Available

Yes

Specimen

Specimen Type

Plasma

Specimen Required**Patient Preparation:**

1. Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.
2. Patient should be fasting 10 hours prior to collection. Patient may drink plain water, no other liquid is acceptable.

Specimen Type: Plasma**Container/Tube:** Z tube (MCL T701)**Specimen Volume:** 3 mL**Collection Instructions:** Draw 10 mL of blood in special Z-tube, pre-chilled (MCL T701). Separate plasma from cells immediately after draw and freeze immediately after separation. Send 3 mL of plasma frozen in a plastic vial.**Specimen Minimum Volume**

1 mL

Reject Due To

Hemolysis	Mild reject; Gross reject
Lipemia	Mild reject; Gross reject
Icterus	NA
Other	Specimens other than collected in Z tube (MCL T701).

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Plasma	Frozen	60 days	

Clinical & Interpretive

Clinical Information

Pancreastatin is a 49 amino acid peptide produced by degradation of Chromo-granin A. It inhibits Chromogranin A and Parathyroid Hormone release. Pancreastatin also inhibits release of Somatostatin upon glucose stimulation. It may also control carbohydrate metabolism and hyperglycemia. Although there are no compounds with significant structural homology with Pancreastatin, there are minor similarities to Gastrin and Anti-Diuretic Hormone. Pancreastatin reduces the early phase of Glucose induced Insulin release. Suppression of Insulin release upon Glucose stimulation is a characteristic feature of Type II Diabetes. Pancreastatin could play an important therapeutic role in the treatment of diabetes. Pancreastatin also inhibits release of Somatostatin. It may also control carbohydrate metabolism and hyperglycemia.

Reference Values

10-135 pg/mL

Clinical Reference

1. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. *Pancreas*. 2012;41(4):508-511.
2. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human Pancreastatin assay to monitor neuroendocrine tumor behavior. *Pancreas*. 201;39(5):611-616.
3. Pier E, Mirelles P, Silvestre RA, et al. Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal polypeptide, gastric inhibiting peptide, and 8-cholecystokinin in the perfused rat pancreas. *Metabolism*. 1989;38:679-82.
4. Tatemoto K, Efendi S, Mutt S, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. *Nature*. 1986;324:476-8.
5. Calhoun K, Toth-Fejel S, Chee J, et al. Serum peptide profiles in patients with carcinoid tumors. *Am J Surg*. 2003;186(1):28-31.
6. Syverson U, Jacobsen MN, O'Connor DT, et al. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. *Neuropeptides*. 1994;26(3):201-6.
7. Kogner P, Bjellerup P, Svensson T, et al. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. *Eur J Cancer* 1995;31A(4):557-60.
8. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analog therapy in metastatic neuroendocrine tumors. *Regul Pept*. 2001;96(3):113-17.

Performance

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

9 to 11 days

Performing Laboratory Location

Inter Science Institute

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

Test Classification

This radioimmunoassay was developed and its performance characteristics determined by Inter Science Institute. It has not been cleared or approved by the FDA and such approval or clearance is not required at this time. Values obtained with different methods, different laboratories or with kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

CPT Code Information

83519

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
FPANP	Pancreastatin, Plasma	49013-6

Result ID	Test Result Name	Result LOINC® Value
FPANP	Pancreastatin, Plasma	49013-6